rs104893720
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The ENST00000264734.3(CLDN16):c.235C>T(p.Arg79Ter) variant causes a stop gained change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00000205 in 1,461,868 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★). Variant results in nonsense mediated mRNA decay.
Frequency
Consequence
ENST00000264734.3 stop_gained
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 18 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
CLDN16 | NM_006580.4 | c.235C>T | p.Arg79Ter | stop_gained | 3/5 | ENST00000264734.3 | NP_006571.2 | |
CLDN16 | NM_001378492.1 | c.235C>T | p.Arg79Ter | stop_gained | 7/9 | NP_001365421.1 | ||
CLDN16 | NM_001378493.1 | c.235C>T | p.Arg79Ter | stop_gained | 6/8 | NP_001365422.1 | ||
CLDN16 | XM_047447333.1 | c.235C>T | p.Arg79Ter | stop_gained | 5/7 | XP_047303289.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
CLDN16 | ENST00000264734.3 | c.235C>T | p.Arg79Ter | stop_gained | 3/5 | 1 | NM_006580.4 | ENSP00000264734 | P1 | |
CLDN16 | ENST00000456423.2 | c.115-5124C>T | intron_variant | 1 | ENSP00000414136 | |||||
CLDN16 | ENST00000468220.1 | n.427C>T | non_coding_transcript_exon_variant | 5/5 | 4 |
Frequencies
GnomAD3 genomes Cov.: 31
GnomAD3 exomes AF: 0.00000398 AC: 1AN: 251490Hom.: 0 AF XY: 0.00000736 AC XY: 1AN XY: 135920
GnomAD4 exome AF: 0.00000205 AC: 3AN: 1461868Hom.: 0 Cov.: 32 AF XY: 0.00000275 AC XY: 2AN XY: 727238
GnomAD4 genome Cov.: 31
ClinVar
Submissions by phenotype
Primary hypomagnesemia Pathogenic:5
Pathogenic, no assertion criteria provided | clinical testing | Biochemical Molecular Genetic Laboratory, King Abdulaziz Medical City | Jul 10, 2018 | - - |
Pathogenic, no assertion criteria provided | literature only | OMIM | Jul 02, 1999 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Dec 24, 2021 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Centogene AG - the Rare Disease Company | - | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Center for Genomic Medicine, King Faisal Specialist Hospital and Research Center | Mar 26, 2024 | - - |
not provided Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Oct 22, 2023 | This sequence change creates a premature translational stop signal (p.Arg149*) in the CLDN16 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in CLDN16 are known to be pathogenic (PMID: 10390358, 10878661, 18003771, 25852890). This variant is present in population databases (rs104893720, gnomAD 0.0009%). This premature translational stop signal has been observed in individuals with hypomagnesemia (PMID: 10390358, 32860008). ClinVar contains an entry for this variant (Variation ID: 5925). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. For these reasons, this variant has been classified as Pathogenic. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at